Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

NASDAQ:PRME

Prime Medicine, Inc.

Last Close

3.50

25/09 14:38

Market Cap

666.17M

Beta: -

Volume Today

173.35K

Avg: 197.03K

PE Ratio

−3.44

PFCF: −3.82